Galileo – Biotech Innovation Fund RM USD

Reference Data

ISIN LU2462149217
Valor Number
Bloomberg Global ID
Fund Name Galileo – Biotech Innovation Fund RM USD
Fund Provider IPConcept (Luxemburg) S.A. Zürich, Switzerland
Phone: +352 260248-1
E-Mail: info.lu@ipconcept.com
Web: www.ipconcept.com
Fund Provider IPConcept (Luxemburg) S.A.
Representative in Switzerland IPConcept (Schweiz) AG
Zürich
Phone: +41 044 224 32 09
Distributor(s) Bellecapital AG
Asset Class Equities
EFC Category
Distribution Policy Accumulation
Home Country Luxembourg
Issuing Condition The fund charges a transaction fee (contribution towards expenses incurred in the investment of new assets)
Redemption Condition The fund management company and/or distributor charges a redemption commission (different commissions can be charged for the same fund depending on the sales channel)
Investment Strategy *** The objective of the investment policy for the sub-fund is to achieve an appropriate level of growth in the sub-fund currency while taking the investment risk into account. The sub-fund is actively managed. The composition of the portfolio is determined by the Fund Manager solely in accordance with the criteria laid down in the investment objectives / the investment policy, is regularly reviewed and, if necessary, adjusted. The sub-fund is not managed using an index as a benchmark.
Peculiarities

Fund Prices

Current Price * 89.81 USD 27.08.2025
Previous Price * 89.23 USD 26.08.2025
52 Week High * 117.56 USD 20.09.2024
52 Week Low * 65.91 USD 09.04.2025
NAV * 89.81 USD 27.08.2025
Issue Price * 89.81 USD 27.08.2025
Redemption Price * 89.81 USD 27.08.2025
Closing Price *
Indicative Minimum Price
Fund Assets *** 29,093,303
Unit/Share Assets *** 13,112
Trading Information SIX

Performance

YTD Performance -4.07% 30.12.2024
27.08.2025
YTD Performance (in CHF) -14.71% 30.12.2024
27.08.2025
1 month +1.42% 28.07.2025
27.08.2025
3 months +19.27% 27.05.2025
27.08.2025
6 months +3.75% 27.02.2025
27.08.2025
1 year -24.27% 27.08.2024
27.08.2025
2 years -40.56% 11.03.2024
27.08.2025
3 years - -
5 years - -

Tax Data

Equity Participation Rate in %
Share of Total Fund Assets in %
Real Estate Rate in %
ADDI
ADDI Date

Top 10 Holdings ***

Krystal Biotech Inc 8.96%
Arcellx Inc 7.88%
Alnylam Pharmaceuticals Inc 5.41%
BioNTech SE ADR 4.87%
Vertex Pharmaceuticals Inc 4.50%
Regeneron Pharmaceuticals Inc 4.00%
Stoke Therapeutics Inc 3.71%
Moderna Inc 3.49%
Sarepta Therapeutics Inc 3.16%
uniQure NV 2.64%
Last data update 31.01.2025

Cost / Risk

TER *** 2.07%
TER date *** 30.06.2025
Performance Fee ***
PTR
Max. Management Fee *** 1.60%
Ongoing Charges *** 2.50%
SRRI ***
SRRI date *** 31.07.2025

Breakdowns

Equity Countries ***

Equity Sectors ***

Bond Sectors ***


* NAV / Issue Price exclusive commissions, for listed funds NAV or closing price
** Calculation of interim profit followed § 9 Satz 2 InvStG
*** Data source: Morningstar (Data is based on the rescaled long position of the holdings)